Author:
Elsayed Noha S.,Valenzuela Robert K.,Kitchner Terrie,Le Thao,Mayer John,Tang Zheng-Zheng,Bayanagari Vishnu R.,Lu Qiongshi,Aston Paula,Anantharaman Karthik,Shukla Sanjay K.
Abstract
AbstractMultiple sclerosis (MS) is a complex autoimmune disease in which both the roles of genetic susceptibility and environmental/microbial factors have been investigated. More than 200 genetic susceptibility variants have been identified along with the dysbiosis of gut microbiota, both independently have been shown to be associated with MS. We hypothesize that MS patients harboring genetic susceptibility variants along with gut microbiome dysbiosis are at a greater risk of exhibiting the disease. We investigated the genetic risk score for MS in conjunction with gut microbiota in the same cohort of 117 relapsing remitting MS (RRMS) and 26 healthy controls. DNA samples were genotyped using Illumina’s Infinium Immuno array-24 v2 chip followed by calculating genetic risk score and the microbiota was determined by sequencing the V4 hypervariable region of the 16S rRNA gene. We identified two clusters of MS patients, Cluster A and B, both having a higher genetic risk score than the control group. However, the MS cases in cluster B not only had a higher genetic risk score but also showed a distinct gut microbiome than that of cluster A. Interestingly, cluster A which included both healthy control and MS cases had similar gut microbiome composition. This could be due to (i) the non-active state of the disease in that group of MS patients at the time of fecal sample collection and/or (ii) the restoration of the gut microbiome post disease modifying therapy to treat the MS. Our study showed that there seems to be an association between genetic risk score and gut microbiome dysbiosis in triggering the disease in a small cohort of MS patients. The MS Cluster A who have a higher genetic risk score but microbiome profile similar to that of healthy controls could be due to the remitting phase of the disease or due to the effect of disease modifying therapies.
Funder
Marshfield Clinic Research Foundation
Institute for Clinical and Translational Research, University of Wisconsin, Madison
Publisher
Springer Science and Business Media LLC
Reference61 articles.
1. Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. (Houndmills Basingstoke Engl. 2020/11/11 ed. SAGE Publications) 26, 1816–1821 (2020).
2. Kozhieva, M. et al. Primary progressive multiple sclerosis in a Russian cohort: Relationship with gut bacterial diversity. BMC Microbiol. BioMed. Central 19, 309–309 (2019).
3. Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502–1517 (2008).
4. Cosorich, I. et al. High frequency of intestinal T(H)17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci. Adv. (American Association for the Advancement of Science) 3, e1700492–e1700492 (2017).
5. Berer, K. et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc. Natl. Acad. Sci. USA (2017/09/11 ed. National Academy of Sciences) 114, 10719–10724 (2017).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献